Ustekinumab as induction and maintenance therapy for ulcerative colitis – national extended follow-up and a review of the literature

Meta‐analysis: Real‐world effectiveness and safety of ustekinumab in patients with ulcerative colitis

(2023) Carlos Taxonera et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

OP15 Efficacy of ustekinumab for Ulcerative Colitis through 4 years: Final clinical and endoscopy outcomes from the UNIFI long-term extension

(2023) S Danese et al.   Journal of Crohns & Colitis

The Role of the Microbiome in the Etiology of Inflammatory Bowel Diseases

(2023) Ariel Halper-Stromberg et al.   Clinics in Colon and Rectal Surgery

Australian inflammatory bowel disease consensus statements for preconception, pregnancy and breast feeding

(2023) Robyn Laube et al.   GUT

Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis

(2022) Steven R. Ytterberg et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pregnancy outcomes following periconceptional or gestational exposure to ustekinumab: Review of cases reported to the manufacturer's global safety database

(2022) Uma Mahadevan et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Ustekinumab for the treatment of moderate to severe ulcerative colitis: a multicentre UK cohort study

(2022) Sailish Honap et al.   Frontline Gastroenterology

Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial

(2022) Bruce E Sands et al.   LANCET

European Crohn’s and Colitis Guidelines on Sexuality, Fertility, Pregnancy, and Lactation

(2022) Joana Torres et al.   Journal of Crohns & Colitis

Effectiveness and Safety Profiles of Biological Therapies in Inflammatory Bowel Disease: Real Life Data from an Active Pharmacovigilance Project

(2022) Maria Antonietta Barbieri et al.   Biomedicines

Use of medications during pregnancy and breastfeeding for Crohn’s disease and ulcerative colitis

(2021) Robyn Laube et al.   Expert Opinion On Drug Safety

Five-year Efficacy and Safety of Ustekinumab Treatment in Crohn’s Disease: the IM-UNITI trial

(2021) William J. Sandborn et al.   Clinical Gastroenterology and Hepatology

Paternal Exposure to Immunosuppressive and/or Biologic Agents and Birth Outcomes in Patients With Immune-Mediated Inflammatory Diseases

(2021) Joseph Meserve et al.   GASTROENTEROLOGY

Effectiveness and safety of ustekinumab in ulcerative colitis: Real-world evidence from the ENEIDA registry

(2021) María Chaparro et al.   Journal of Crohns & Colitis

Superior treatment persistence with ustekinumab in Crohn’s disease and vedolizumab in ulcerative colitis compared with anti‐TNF biological agents: real‐world registry data from the Persistence Australian National IBD Cohort (PANIC) study

(2021) Yanna Ko et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Effectiveness and safety of ustekinumab maintenance therapy in 103 patients with ulcerative colitis: a GETAID cohort study

(2021) Mathurin Fumery et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

One-year effectiveness and safety of ustekinumab in Ulcerative Colitis: a multicenter real-world study from Italy

(2021) Michele Francesco Chiappetta et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Safety of drugs used for the treatment of Crohn’s disease

(2019) Aviv Pudipeddi et al.   Expert Opinion On Drug Safety

Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis

(2019) Bruce E. Sands et al.   NEW ENGLAND JOURNAL OF MEDICINE

Ustekinumab as Induction and Maintenance Therapy for Crohn’s Disease

(2016) Brian G. Feagan et al.   NEW ENGLAND JOURNAL OF MEDICINE

Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up

(2013) K.A. Papp et al.   BRITISH JOURNAL OF DERMATOLOGY

Development in the cynomolgus macaque following administration of ustekinumab, a human anti-il-12/23p40 monoclonal antibody, during pregnancy and lactation

(2010) Pauline L. Martin et al.   BIRTH DEFECTS RESEARCH PART B-DEVELOPMENTAL AND REPRODUCTIVE TOXICOLOGY